Can Treg therapy prevent GVHD?

Krishna V Komanduri, Richard E. Champlin

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.

Original languageEnglish
Pages (from-to)751-752
Number of pages2
JournalBlood
Volume117
Issue number3
DOIs
StatePublished - Jan 20 2011

Fingerprint

Regulatory T-Lymphocytes
Immunosuppressive Agents
Fetal Blood
Blood
Transplants
Safety
T-cells
Grafts
Pharmaceutical Preparations
Rocks
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Can Treg therapy prevent GVHD? / Komanduri, Krishna V; Champlin, Richard E.

In: Blood, Vol. 117, No. 3, 20.01.2011, p. 751-752.

Research output: Contribution to journalArticle

Komanduri, Krishna V ; Champlin, Richard E. / Can Treg therapy prevent GVHD?. In: Blood. 2011 ; Vol. 117, No. 3. pp. 751-752.
@article{a5d89a27190e46498f501167d9e21d7c,
title = "Can Treg therapy prevent GVHD?",
abstract = "In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.",
author = "Komanduri, {Krishna V} and Champlin, {Richard E.}",
year = "2011",
month = "1",
day = "20",
doi = "10.1182/blood-2010-11-317305",
language = "English",
volume = "117",
pages = "751--752",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Can Treg therapy prevent GVHD?

AU - Komanduri, Krishna V

AU - Champlin, Richard E.

PY - 2011/1/20

Y1 - 2011/1/20

N2 - In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.

AB - In this issue of Blood, Brunstein and colleagues report the results of the first study to test the safety of human umbilical cord blood - derived regulatory T cells (Tregs), an approach designed to decrease graft-versus-host disease.1 Transplanters, like Sisyphus of myth, have struggled mightily with trials of pharmacologic immunosuppressive drugs - we roll the rock up the mountain, only to see it roll back, leaving us where we began. This struggle has now led us to seek cellular therapies as a promising alternative.

UR - http://www.scopus.com/inward/record.url?scp=78751691629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751691629&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-11-317305

DO - 10.1182/blood-2010-11-317305

M3 - Article

C2 - 21252098

AN - SCOPUS:78751691629

VL - 117

SP - 751

EP - 752

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -